Clear cell ovarian carcinoma (CCOC) and clear cell renal cell carcinoma (ccRCC) both feature clear cytoplasm, owing to the accumulation of cytoplasmic glycogen. Genomic studies have demonstrated several mutational similarities between these two diseases, including frequent alterations in the chromatin remodelling SWI-SNF and cellular proliferation phosphoinositide 3-kinase-mammalian target of rapamycin pathways, as well as a shared hypoxia-like mRNA expression signature. Although many targeted treatment options have been approved for advanced-stage ccRCC, CCOC patients are still treated with conventional platinum and taxane chemotherapy, to which they are resistant. To determine the extent of similarity between these malignancies, we performed unsupervised clustering of mRNA expression data from these cancers. This review highlights the similarities and differences between these two clear cell carcinomas to facilitate knowledge translation within future research efforts.
Introduction
Clear cell carcinomas (CCCs) of the ovary and kidney share morphological similarities, including cytoplasmic glycogen storage. In this review, through an exploration of clinical, pathological and genomic characteristics, including an integrated analysis of mRNA expression data, we aim to determine whether the similarity between these cancer types is more than superficial. Also, we visit the past, current and future treatment options for these malignancies. Although these cancers are not identical, we establish the molecular rationale for knowledge transfer between these malignancies, and thus the potential to fast-track advances made in the management of one cancer type to the other.
Clinical features and histopathology

Clear cell ovarian carcinoma
Epithelial ovarian carcinoma (EOC) is the fifth leading cause of death from cancer for women in the USA [1] . Clear cell ovarian cancer (CCOC) is a distinct entity within the EOCs [2] , and accounts for 5-11% of cases of EOC in North America and 24.8% in Japan [3] . Endometriosis is an established risk factor for CCOC [4, 5] . A strong reduction in CCOC incidence is associated with multiparity, the use of menopausal hormone therapy, and hysterectomy [6] , all of which also impact on endometriosis. Interestingly, whereas smoking is associated with an increased risk of other EOC subtypes, it is protective against CCOC [6] . This point, although trivial from a public health perspective, underscores how different CCOC is from other EOC subtypes and from clear cell renal cell carcinoma (ccRCC), which is strongly associated with smoking.
CCOC is diagnosed in younger patients than other EOC subtypes (median age of 57 years) [7] , and at an earlier stage [8, 9] . For patients with CCOC, a lower stage confers a survival advantage, with patients with stage I-II disease having a median survival of 31.8 months, as compared with 12.7 months and 17.8 months for those with stage III and IV disease, respectively [9] . At a late stage, patients with CCOC have a worse prognosis than those with other EOC subtypes, partially owing to a lack of response to conventional chemotherapy [9] [10] [11] . Other factors predictive of a worse outcome include suboptimal surgical debulking [9] and ovarian surface involvement [8] . lack frequent or abnormal mitosis and other features of high-grade carcinomas. The presence of cells with clear cytoplasm and hobnailed cells is common [7] , giving this cancer its name, and making the diagnosis robust even prior to introduction of the World Health Organization 2014 criteria [12] . The clear cytoplasm is filled with glycogen deposits, and stains positively with periodic acid-Schiff stain [13] . The immunohistochemical (IHC) profile of CCOC includes positive immunostaining for hepatocyte nuclear factor-1β (HNF1b) and napsin A, and an absence of immunostaining for Wilms tumour 1 and oestrogen receptor [14, 15] . Kisspeptin and IMP3 are prognostic in CCOC but not in other ovarian cancer subtypes [16, 17] .
Clear cell renal cell carcinoma
Renal cancer is the 12th most common cancer worldwide [18] , and has a higher incidence in developed countries [19] . Renal cancer is more common in males than in females (1.5:1 ratio), making it the ninth most common cancer in men, and the 14th in women [18] . ccRCC is the most common subtype, accounting for 75% of all kidney cancers [20] , and being responsible for 78 000 cases yearly in the USA. Significant risk factors for ccRCC include being male, obesity, a history of smoking, and end-stage kidney damage [21] , in addition to exposure to some environmental factors, such as trichloroethylene [22, 23] . The development of ccRCC is associated with von Hippel-Lindau (VHL) syndrome, a rare genetic condition caused by a mutation in VHL, in <2% of cases [24, 25] . In addition to VHL syndrome, there is a strong familial component to ccRCC, with a 4.3-fold increased risk of RCC development if there is a history of kidney cancer in first-degree relatives [26] .
The average age at diagnosis of ccRCC is 62.5 years. Owing to abdominal imaging being frequently used, an increasing number of patients are being diagnosed at stage I and with small incidental tumours [27] [28] [29] . Many risk stratification systems have been developed to predict renal cell carcinoma (RCC) patient outcome for both localized and metastatic disease [30] [31] [32] .
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all RCC subtypes is tumour size, with patients with localized tumours smaller than 4 cm having a 97% 10-year disease-free survival rate after partial nephrectomy [34] . Localized unilateral tumours between the size of 4 and 7 cm are also managed surgically [35, 36] , making early-stage RCC a surgically treatable disease. Histological nuclear grade is a strong predictor of outcome, as patients with localized larger tumours with lower nuclear grade may have better survival than those with their higher-grade counterparts [37] . The 5-year disease-specific survival rate for advanced-stage cancer patients with larger tumours with local or distant spread is <30%, despite recent therapeutic advances [32] .
Histologically, much like CCOC, ccRCC usually contains cells with glycogen-filled clear cytoplasm (Figure 1 ). ccRCC can feature several microscopic architectures, including solid, alveolar and acinar patterns [38] . Rarely, ccRCC contains sarcomatoid components, which mark a worse outcome. Histopathological evaluation of ccRCC and nuclear grading based on cancer nuclei pleomorphism is a crucial factor for the prognostic evaluation of patients [38] . The immunoprofile of ccRCC includes positive staining for RCC markers, CD10, brush border antigens, low molecular weight cytokeratins, and mucins 1 and 3 [38] .
CCCs of other anatomical sites
Other CCCs from the gynaecological tract are endometrial CCC, which is a rare subtype of uterine cancer, and CCCs of the vagina and cervix, which are associated with in utero diethylstilboestrol exposure [39] . All gynaecological CCCs are morphologically similar [40] . It is of note that endometrial CCCs share genomic subgroups with endometrioid endometrial carcinomas, although with distinct subgroup distributions [41] . As may be the case for CCCs and endometrioid ovarian carcinomas (ENOCs), the difference between their uterine counterparts may be due to distinct cells of origin rather than acquired oncogenic features [42] .
Clear cell variants exist for many other carcinomas in the body, but are extremely rare. Case reports have documented clear cell variants of carcinomas of the bladder [43] , the skin [44] , the testis [45] , the thyroid [46] , and the salivary glands [47] . Owing to the rarity of these clear cell variants, their molecular and genomic landscapes are not well characterized. Although interesting research questions are associated with these variants, they will not be discussed herein.
Genomic landscape
Clear cell ovarian carcinoma
Unlike the most common EOC subtype, high-grade serous carcinoma (HGSC), CCOCs have a relatively quiet genome, rarely harbour TP53 mutations [48] [49] [50] , and are less frequently mutated in BRCA1/2 [51, 52] . Targeted polymerase chain reaction-based studies identified an activating mutation in PIK3CA in 33-45% of cases [53, 54] , associated with a lower stage at diagnosis and a better outcome [55, 56] . The phosphoinositide 3-kinase (PI3K) cascade is important in cellular proliferation upon activation by upstream receptor tyrosine kinase (RTK) family receptors [57] . Other mechanisms of activation of the RTK-RAS-PI3K pathway reported in CCOCs include PTEN loss [58] , AKT amplification [59] , increased mammalian target of rapamycin (mTOR) phosphorylation [60] , and point mutations in the KRAS oncogene [61] . These findings suggest a major role of the PI3K-AKT-mTOR pathway in the oncogenesis of CCOC.
Whole transcriptome sequencing has revealed somatic mutations in ARID1A in 46-57% of CCOCs [62, 63] , correlating with ARID1A protein (BAF250) loss [64] . ARID1A is a member of the SWI-SNF complex, which is crucial in chromatin remodelling and epigenetic regulation of a myriad of target genes [65] . Aside from ARID1A, other members of the SWI-SNF complex are altered either by mutation or by loss of expression, highlighting the oncogenic role of SWI-SNF aberration [66] . There are discrepancies in the clinical significance of ARID1A loss, with some studies showing a correlation with advanced stage and worse survival [67, 68] , and others showing no clinical implications [64, 69] . The frequent co-occurrence of PIK3CA and ARID1A alterations in CCOCs [70] [71] [72] prompted molecular studies into its oncogenesis. Weigand et al showed that loss of ARID1A correlated with increased AKT phosphorylation, regardless of PI3K and PTEN expression [73] , suggesting that the SWI-SNF complex interacts with the PI3K pathway. In a murine model with ARID1A conditionally knocked out, coexistent ARID1A loss and PIK3CA activating mutation is sufficient to promote CCOC initiation through interleukin (IL)-6 upregulation [74, 75] . This finding resonates with previous findings showing IL-6-STAT3-hypoxia-induced factor (HIF) pathway upregulation in CCOC as compared with HGSC, along with an increased circulating IL-6 level in patients [76] .
Other recurrent genomic and chromosome aberrations in CCOC have been reported. Approximately 7% of CCOCs have mutations in PPP2R1A, which encodes a protein involved in cellular proliferation [63, 77] . Several important focal copy number changes have been identified in CCOC. An amplification of 17q21-24 associated with poorer outcome was identified in 40% of patients [78] . Other genes in chromosome 17, including the oncogene PPM1D, are amplified in 10% of CCOCs [79] , and microRNA-21 is overexpressed in 14%, resulting in loss of PTEN [80] . Focal amplification of chromosomes 3q12-29 and 8p23 was observed in a cohort of Japanese and Chinese CCOCs [81] . Exome sequencing and array comparative genomic hybridization also identified frequent arm-level copy number changes, including amplification in chromosomes 8p (64%), 20q
Ovarian and renal clear cell carcinomas 553 sequencing of seven CCOC tumours identified deletions in chromosomes housing RB1, NOTCH1, and a few genes encoding members of the SWI-SNF complex [83] . Exome sequencing identified 26% of CCOC patients with amplifications in the CCNE1 locus, whose copy number gain was previously shown to be correlated with increased protein expression, and associated with a worse outcome [84] . Together, these findings show that the genomic landscape of CCOC is shaped by both mutations and chromosomal alterations.
The first detailed analysis of the genomic landscape of CCOC was published in 2017. In this study, whole genome sequencing data from 35 CCOCs with matched normal tissue were compared with those derived from other ovarian cancer subtypes [85] . In this analysis, CCOC was mainly stratified into two subgroups by mutational signatures. Whereas 26% of CCOCs were enriched in an APOBEC mutational signature, the age-related signature was predominant in 40%. The APOBEC family of enzymes are cytidine deaminases with important roles in post-transcriptional RNA and single-stranded DNA editing [86] , and have been shown to contribute to mutagenesis in human cancers [87] . The establishment of an APOBEC mutational signature characterized by C-to-G conversion mutations at double-stranded DNA repair sites [88, 89] in a proportion of CCOCs provides clues to the oncogenic mechanisms driving this cancer, but the timing of these events is not known.
The genomic complexity of this cancer is still underexplored, and genomic events underpinning cases without ARID1A or PIK3CA mutations are unknown. Further discoveries will probably be derived from analysis of intronic and other non-coding mutations, and from the integration of other -omic data, such as epigenomic, proteomic and metabolomic data.
Clear cell RCC
ccRCC has a strong genetic component. A small proportion of ccRCC patients have VHL disease, which is caused by germline inactivating mutations in the VHL tumour suppressor gene [90, 91] . Patients with VHL develop ccRCC and haemangioblastomas as a result of a second VHL mutation, or loss of the remaining functional allele of VHL [92] . The importance of this gene in ccRCC is underscored by the 42-57% of sporadic ccRCCs that show de novo mutations in VHL [93, 94] , and the 11-21% of cases found to to have inactivation of VHL through hypermethylation [95, 96] . Strikingly, up to 98% of ccRCCs harbour a loss of heterozygosity (LOH) in chromosome 3p, where VHL is located [93] [94] [95] . VHL protein (pVHL) is crucial for the ubiquitylation and subsequent degradation of HIF1α and HIF2α in normoxic conditions [97, 98] . Loss of function of pVHL therefore results in accumulation of HIF1α and HIF2α, and uncontrolled downstream transcriptional activation. Dysregulation of HIF proteins is key to ccRCC pathogenesis, as mutations in VHL that do not impact on HIF function are not associated with ccRCC risk [99] . Many molecular studies have supported the role of HIF1α and HIF2α in the oncogenesis and maintenance of ccRCC [100, 101] , indicating that a 'hypoxia-mimic' phenotype is a crucial driver of this cancer. Although CCOC arguably shares this hypoxia-mimic phenotype, VHL has never been implicated in CCOC.
The observations that approximately 10-20% of ccRCCs do not have VHL alterations other than LOH of chromosome 3p [96, 102] and that Vhl-null mice do not develop ccRCC [103] prompted investigation into other possible oncogenic drivers. Dalgliesh et al identified significant somatic alterations in five genes related to chromatin modification (SETD2, KDM5C, NF2, UTX, and MLL2), and demonstrated mRNA expression changes upon specific chromatin modifier mutations in patient tumour samples [104] . The same group, using capture-based exome sequencing, identified somatic point and truncating mutations in the SWI-SNF complex member gene PBRM1 in 41% of ccRCC tumours that showed a hypoxic signature [105] . Furthermore, 70% of ccRCCs were found to harbour either PBRM1 or BAP1 loss, with the mutation frequency of BAP1 being 14% [106] . Aside from its roles in chromatin remodelling complexes and cell proliferation suppression, loss of the histone deubiquitinase BAP1 was shown to sensitize ccRCC cell lines to radiation and poly(ADP-ribose) polymerase inhibitors [106] . The near mutual exclusivity of the loss of these two proteins separates ccRCC into distinct clinically significant molecular subgroups [106, 107] . Patients with BAP1-mutated tumours were found to have a worse prognosis than those with PRBM1-mutated tumours, and the few cases with both BAP1 and PRBM1 mutations had the worst outcome [107] . In addition, ARID1A expression was decreased in 68% of ccRCC patients, and was associated with worse outcomes [108] . Over recent years, the genomic landscape of ccRCC has continued to be described in greater detail. In a whole exome study, frequent mutations in members of the ubiquitin-mediated proteolysis pathway, which is a pathway important in the degradation of HIF1α and HIF2α by pVHL, were identified [109] . Alterations in this pathway increases the hypoxia response through HIF1 [109] . Single-cell sequencing of samples from a patient without VHL or PRBM1 mutation revealed mutations in genes of the chromatin remodelling (AHNAK) and proteolytic (USP6) pathways, further supporting the importance of these pathways in ccRCC biology [110] .
As part of an effort to characterize the genome of cancers, The Cancer Genome Atlas (TCGA) Project sequenced 400 ccRCCs. This study showed a higher incidence of arm-level chromosomal alterations than of focal events in ccRCC [111] . In addition to chromosome 3p loss, the study identified frequent loss of chromosome 14q, which has been previously shown to result in HIF1A loss and more aggressive disease. The authors characterized the frequent chromosome 5 amplification (67% of cases) to identify 60 potential target genes on chromosome 5q35, previously shown to include 554 JX Ji et al FGFR4, which encodes a growth factor receptor in the mTOR pathway [96, 111] . Mutually exclusive alterations in other members of the PI3K-mTOR pathway were also seen in 28% of ccRCCs. Analysis of the methylation profiles revealed multigene epigenetic silencing in 5% of the tumours, and an association between DNA methylation loss and SETD2 mutation. On the basis of its mRNA expression, ccRCC was separated into four clusters, each with unique clinical and genomic features. The heterogeneity of ccRCC observed from mRNA expression data was previously noted [112] , but the study on a larger cohort refined these clusters, providing a comprehensive view of its expression landscape.
The clonal evolution of ccRCC was demonstrated by multiregion exome sequencing [113] , which showed that ccRCCs have a branched evolution and diverse intratumour genomic features. VHL and PBRM1 alterations were early events in ccRCC tumourigenesis. Parallel evolution between spatially separate clones converged to mutations in PIK3CA, BAP1, ARID1A or genes encoding other members of the SWI-SNF complex [113] . These distinct subclonal mutational profiles between clones demonstrated the complexity of ccRCC biology. To date, the genomic evolution of CCOC during progression has not been studied in such detail.
Cells of origin
Clear cell ovarian carcinoma
The cells of origin of ovarian carcinomas have been the subject of debate in recent years; several review articles have addressed this complex subject extensively [114, 115] . Indeed, the ovary is unique, in that the most common cancers occurring in this organ are derived from cells not native to it. Whereas HGSCs are thought to arise from serous tubal in situ carcinomas from the fallopian tube [116] , CCOC and ENOC are associated with and often seen to arise directly from ovarian endometriotic cysts, particularly from atypical endometriosis [117] . Multiple studies have shown that a genomic feature found in an endometriosis-associated cancer is also present in the adjacent endometriotic epithelium [62, 70, 118, 119] . Indeed, in some cases, the endometriotic lesion can share a nearly complete complement of lesions with the adjacent CCOC [83] . These data suggest that transformation of ovarian endometriotic epithelium to carcinoma is driven by the acquisition of mutations in well-known cancer genes, and that ovarian endometriotic cysts are particularly susceptible, owing to the mutagenic environment that they create [115] . More recently, the finding of canonical cancer mutations in other forms of endometriosis, especially deep infiltrating endometriosis (DIE), have indicated that at least some mutations may arise in utero before the seeding of endometriosis [120] . Although the copy number alterations seen in CCOCs have not yet been seen in DIE lesions, three patients in this study had similar mutational signatures to those expected in CCOC, of which two had inactivating mutation of ARID1A and one had concurrent activating mutations in PIK3CA, KRAS, and PPP2R1A in the endometriotic epithelium [120] . More research will be required to determine the role of these mutations in oncogenesis and how the ovarian microenvironment gates and shapes oncogenic opportunity.
The question of how two distinct cancers such as CCOC and ENOC could arise from the same precursor lesions was thought to be explainable through genomic differences. However, although these cancers have distinct genomic profiles, there is no single genomic feature found in one cancer type and not the other. An alternative hypothesis, that the distinct pathologies of CCOC and ENOC may be due to different cells of origin within endometriosis, has been raised in this journal [42] . In this model, whereas ENOC arises from secretory-like cells, CCOC shares features with ciliated cells, and may arise from cells of that lineage.
Clear cell RCC
The origin of ccRCC is better established than that of ovarian cancers. The evidence is in support of ccRCCs arising from the epithelium of the proximal convoluted tubules [121, 122] . In patients with VHL syndrome, molecular genetics studies have demonstrated that benign and atypical renal cysts show biallelic inactivation of VHL, suggesting that these cysts are precursors of ccRCC [123] .
Knowledge about cell of origin, complemented by recent genomic discoveries, drastically improved our ability to generate animal models for ccRCC. Mice with conditional homozygous deletions of Vhl and Pbrm1 developed ccRCC precursor lesions at 6 months and multifocal ccRCC arising from the proximal convoluted tubule at 10 months, with comparable mRNA expression profiles to that of human ccRCC [124] . As mice deficient in only one of the genes do not develop cancer, there is an epistatic interaction through which the presence of functional Pbrm1 partially rescues the effect of Vhl loss. In mice doubly deficient in Vhl and Pbrm1, the authors noted downregulated expression of oxidative phosphorylation genes, and increased activity of the mTOR pathways. The authors studied the TCGA cohort, and showed the prevalence of mTOR and HIF1 pathway activation in ccRCC patients with VHL and PBRM1 abberations, suggesting a three-hit model whereby aberrations in VHL, PBRM1 and the subsequent mTOR activation are important in ccRCC oncogenesis.
Reanalysis of the TCGA ccRCC data, focusing on cell cycle regulation, identified frequent copy number alterations of members of the p53 regulation and cell cycle checkpoint control clusters [125] . Mutations in SWI-SNF members were not prevalent in this cohort, suggesting a different mechanism of oncogenesis. To this end, triple deletion of Vhl, Trp53 and Rb1 was induced in epithelial cells of mouse nephrons, including the proposed cells of origin for ccRCC: proximal tubule epithelial cells. Remarkably, the mice with loss of all three genes developed multiple ccRCCs and their precursor cystic lesions, like those seen in VHL syndrome patients. These tumours developed faster in male mice than in female mice, and had similar molecular fingerprints as human ccRCC tumours. When studying the mutational landscape of murine ccRCC arising from deletion of the three genes, the authors found a convergence of mutations between the mouse and human ccRCCs, especially mutations in the primary cilia-related genes. The connection of both CCOC and ccRCC to ciliated cells awaits exploration.
Current treatment
Clear cell ovarian carcinoma
The primary treatment for CCOC is surgical debulking, sometimes with postoperative radiation therapy. Despite the advances in the genomic and molecular understanding of ovarian cancer and its diverse subtypes, the therapeutic treatment options for ovarian cancer patients have not evolved: all subtypes are treated with conventional chemotherapy agents. With the ovaries' location in the peritoneal cavity, surgical success can be limited, owing to its lack of biological compartmentalization. Therefore, effective therapeutic agents are urgently needed to improve patient outcome by targeting tumour cells seeded in the peritoneal organs that cannot be removed by surgical debridement.
Although, currently, no targeted therapeutics are approved for CCOC, there are ongoing efforts to explore the many vulnerabilities of this cancer based on the understanding of its genomic landscape. In order to understand the role of IL-6-STAT3-HIF pathways in CCOC oncogenesis, three groups have reported case-based off-label use of sunitinib in refractory CCOC patients. Sunitinib is a small-molecule antiangiogenic vascular endothelial growth factor (VEGF) receptor (VEGFR) inhibitor that is currently approved for first-line therapy in late-stage ccRCC patients. CCOC patients receiving sunitinib all showed initial response to therapy; however, most eventually succumbed to their disease [76, 126, 127] . Similarly, a case report of treatment of two refractory CCOC patients with another VEGFR inhibitor, sorafenib, also showed partial responses [128] . Many similar trials aimed at exploiting the angiogenic pathway in CCOC are underway, including one study on the use of nintedanib in recurrent endometrial and ovarian clear cell carcinoma patients (NCT02866370), and a phase II study of the use of sunitinib in recurrent CCOC patients (NCT00979992). The Gynecologic Oncology Group completed a phase II clinical trial targeting late-stage CCOC with temsirolimus combined with conventional chemotherapy (NCT01196429/GOG0268); the study results are highly anticipated. In 2015, a phase I trial of the anti-IL-6 receptor monoclonal antibody tocilizumab demonstrated its safety profile when combined with conventional chemotherapy [129] . The authors recommended phase II studies of this agent, which have yet to be initiated. Aside from CCOC-specific trials, many CCOC patients are eligible for trials open to patients with late-stage or recurrent EOC regardless of subtype. Although these trials provide opportunities for CCOC patients, they often lack correlation with molecular findings.
Many in vitro efforts are underway to exploit the molecular vulnerabilities of CCOC, including targeting a synthetic lethal mechanism through EZH2 in ARID1A-mutated cancers [130] , targeting specific proliferative pathways [131] , and applying screening approaches to identify potential therapeutic targets [132] . However, these findings require further validation before clinical consideration.
Clear cell RCC
For lower-stage ccRCC, surgical resection is the gold-standard treatment. In localized tumours smaller than 7 cm, partial nephrectomy is often curative [133] . In the case of locally advanced disease, radical nephrectomy is recommended, with consideration given to clinical trial enrolment for adjuvant cytokine therapy [133] . The development of targeted therapies has mostly been aimed at treating metastatic ccRCC or patients with recurrence, for whom primary treatment still includes cytoreductive surgery whenever indicated. In addition to IL-2 therapy as first-line adjuvant therapy for advanced-stage RCC patients [134] , there is level I evidence supporting therapies targeting the angiogenic pathway. These include pazopanib [135] , sunitinib [136] , and bevacizumab [137] . Many targeted therapies are approved for second-line and third-line treatment of patients who are refractory to previous regimens. A comprehensive overview of treatment options for late-stage ccRCC is provided by the National Cancer Institute's Physician Data Query and the European Society for Medical Oncology treatment guidelines [133, 138] . Despite the development and approval of targeted therapeutics for advanced-stage ccRCC patients, their outcome remains suboptimal, as few therapies provide an overall survival advantage beyond a few months. Nevertheless, many clinical trials are currently underway to identify more effective therapeutics for patients, among which are 60 studies for patients with advanced ccRCC, according to the National Cancer Institute's clinical trial search. In this review, we consider whether knowledge gained in ccRCC will help patients with CCOC. 
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HNF1b
Transcription factor with important roles in the development of several organs, including the liver, kidney, and genital tract; regulates glucose homeostasis [156] Specific marker for CCOC among the EOCs, shown to be essential for CCOC survival through in vitro studies [147] , and associated with clear cell histology in both ovarian and renal cancers [153] HNF1b positivity is associated with renal cancers with clear cell histology as compared with other subtypes [153] Napsin A Aspartic protease expressed in normal lung and kidney [157] . Expression is associated with lung adenocarcinoma [158] Specific marker for CCOC among EOCs [15] Napsin A positivity was found in 34% of ccRCCs and 79% of papillary RCCs [159] 
IMP3
A member of the insulin-like growth factor mRNA-binding protein family. Regulates the translation of target transcripts, including insulin-like growth factor 2 and MYC [160, 161] IHC IMP3 positivity is associated with worse prognosis in CCOC, but not in other subtypes of EOC [17] IMP3 expression is associated with worse outcome in ccRCC [162, 163] *Other clinical IHC markers for CCOC and ccRCC are described in the section 'Clinical features and histopathology'. The IHC markers included in the tables are those that have been characterized in both CCOC and ccRCC. 
CD10
A cell surface metallopeptidase expressed in a wide range of tissues, including endometrial stromal cells and kidney [164] CD10 expression was found in the majority of ccRCCs and papillary RCCs [165] CD10 is largely negative in CCOC, making it a useful maker to differentiate CCOC from metastatic ccRCC [141] CAIX Downstream target of HIF1, an established marker of tumour hypoxia [166] Highly expressed in ccRCC. Although its prognostic value is debated [167] [168] [169] [170] , CAIX expression was shown to be predictive of IL-2 therapy response [171] CAIX has been shown to be expressed at a low level in CCOC [172] *Other clinical IHC markers for CCOC and ccRCC are described in the section 'Clinical features and histopathology'. The IHC markers included in the tables are those that have been characterized in both CCOC and ccRCC.
of these two cancers in order to understand them beyond their morphological similarities. Clinically, although the incidence of renal cancer has increased, the mortality due to this cancer has decreased [19] , partly because of earlier incidental detection, and partly because of increased therapeutic options. In contrast, the mortality due to ovarian cancer has remained high over the past 30 years. Although CCOC is discovered at an earlier stage than other EOC subtypes, 40% of patients are still diagnosed at stage III-IV [9] . Moreover, as conventional taxane-based and platinum-based chemotherapy remain the gold-standard regimen for ovarian carcinomas, the outcome for CCOC patients remains suboptimal, owing to the inherent chemoresistance of this malignancy.
Histologically, CCOC and ccRCC often show similar features, and several groups have studied IHC markers to differentiate the two malignancies [139] [140] [141] . Of these markers, positivity for RCC markers and CD10 were the main factors distinguishing ccRCC from CCOC. Despite these differences, there are also similarities. IHC markers pertinent to CCOC and ccRCC are summarized in Tables 1 and 2 .
As described in this review, ccRCC and CCOC have distinct genomic landscapes ( Figure 2 ). Whereas ccRCC harbours mostly arm-level copy number changes, CCOC is mainly associated with focal events. In ccRCC, a loss of chromosome 3p serves as a 'second hit' to VHL mutation; the concurrent biallelic loss of genes on chromosome 3p, including PBRM1, SETD2, and BAP1, in addition to VHL inactivation, is shown to be sufficient for tumourigenesis [124] . However, pathognomonic mutations associated with the development of CCOC have not been identified, raising the possibility that a more diverse mutational background may be needed for malignant transformation, building upon the foundation set by ARID1A and PIK3CA mutations. Interestingly, CCOCs show mutational signatures corresponding to APOBEC or age-related single-nucleotide changes. In contrast, ccRCC was not found to have an APOBEC mutagenesis pattern [89] .
Despite the differences in background mutational landscapes, the two CCCs share alterations in a few pathways (Figure 2 ). Aside from VHL alterations, the driving mutations in ccRCC are those in the SWI-SNF, PI3K-mTOR, and p53 pathways [96, 111] . Although p53 alterations are uncommon in CCOC, the SWI-SNF and PI3K-mTOR pathways are frequently concurrently mutated, representing early events in tumourigenesis. Mutations in the PI3K and SWI-SNF pathways are unique driver events in the clear cell subtypes as compared with other kidney and ovarian cancers. In ovarian cancers, ARID1A and PIK3CA mutations are driver mutations specific to the endometriosis-associated clear cell and endometrioid cancers. Davis et al have indicated that chromophobe renal carcinomas (chRCCs) are associated with TP53 (32%), PTEN (9%) and TERT promoter alterations (10%) [142] . Chromatin modifier mutations have been found in 20% of papillary RCCs [143] ; however, alterations in this pathway do not seem to be the main driving events. The convergence of driver mutations in both PI3K and SWI-SNF pathways raised Hypoxia plays important roles in the oncogenesis of both CCCs. The loss of pVHL in ccRCC mimics a hypoxic response even in the oxygen-rich environment in the kidney. In this hypoxia-mimic condition, HIF1 protein levels are maintained, owing to a lack of pVHL-mediated degradation. HIF1 then activates angiogenesis processes to increase blood flow to hypoxic tissues, and upregulate proglycolytic pathways while decreasing mitochondrial oxygen demand [144] . Similarly, as CCOC is thought to arise from ovarian endometriotic cysts, it is associated with a hypoxic environment during its tumourigenesis. The presence of blood contained in these cysts as a result of ovulatory cycles subjected the cells to a hypoxic environment full of reactive oxygen species. We hypothesize that the hypoxic environment can alter the biology of ectopic endometrial tissue, pushing it towards malignant transformation in a background of an active ovarian microenvironment. Several groups have shown high expression of proteins involved in the HIF pathways [76, 145] , demonstrating the importance of the hypoxia response in CCOC. To this end, the HIF pathway and its downstream target VEGF have been a focus of therapeutic development in CCOC, where antiangiogenic therapeutics approved to treat ccRCC are being repurposed.
The glycogen-filled cytoplasm of ccRCC cells and its hypoxia-mimic molecular phenotype led to the analysis of its metabolic landscape. In a study profiling the whole metabolome of 138 ccRCCs, Hakimi et al showed alterations in many metabolic processes in tumours as compared with adjacent normal kidney tissues [146] . In this comprehensive study of ccRCC metabolism, the authors identified the upregulation of several metabolic pathways correlating with worse outcome and tumour progression. As similar histological features and activation of HIF pathways have been seen in CCOC, the role of altered metabolism in this cancer is also being investigated. Strong expression of HNF1b, a protein involved in cellular glucose uptake, is unique to CCOC among EOC subtypes [147] . This aberrant expression was found to correlate with loss of promoter methylation in CCOC [148] , and to contribute to survival in hypoxic environments [149] . Furthermore, cystathionine-γ-lyase (CTH) was shown to be highly expressed in CCOC as compared with other ovarian carcinoma subtypes [150] . A further study using CTH as a marker for lineage tracing indicated the cells of origin for CCOC and ENOC to be the ciliated and secretory cells of the endometrial epithelium [42] .
There have been previous attempts to compare the genomic features of ccRCC and CCOC. Zorn et al demonstrated, using unsupervised clustering, that the transcriptomic landscapes of CCCs from the ovary and endometrium were closer to ccRCC than to other ovarian and endometrial cancers [151] . Furthermore, cell lines derived from CCOC and ccRCC have remarkable similarities in their global mRNA expression, prompting an analysis of the effect of the VEGF inhibitors sorafinib and sunitinib in mouse models of CCOC, in which sorafenib significantly hindered tumour growth in vivo [152] . Interestingly, increased HNF1b expression resulting from promoter hypomethylation was found to be a common feature of CCCs of the gynaecological tract and kidney, further implying metabolic similarities between these malignancies [153] .
To further compare gene expression in CCOC and ccRCC, and in particular genes involved in key metabolic pathways, we performed hierarchical clustering on a combined set of 367 TCGA ccRCCs [111] and 62 of our local endometriosis-associated ovarian cancer cases (33 CCOCs and 29 ENOCs) [85] , based on their mRNA expression of the 500 most variable previously predicted metabolic genes [154] . The ccRCCs are stratified into distinct subgroups, and, although this finding mainly agrees with the m1-m4 clusters shown by Creighton et al, who used unsupervised clustering on global mRNA expression profiles [111] , it also identified subgroups within m1-m4 clusters based on the smaller gene set used in this analysis. Although we recognize the limitations of using mRNA expression to infer metabolic pathway activity, we hope that this initial analysis will provide a glimpse into the metabolic intricacies shared by these cancer types. Within this analysis, the CCOCs and ENOCs were scattered among the ccRCCs independently of mutational status, as frequently mutated genes are evenly distributed throughout. The clustering results were similar when unsupervised clustering on whole transcriptome data was performed (results not shown). In a previous study comparing chRCC with ccRCC, unsupervised clustering of transcriptome data separated the two subtypes of renal cancer into distinct clusters [143] . In a study of the transcriptome of ovarian cancers, CCOC also occupies its own cluster apart from the other EOC subtypes [151] . The lack of distinct clustering between ccRCC and CCOC therefore further supports a similarity beyond morphology. Furthermore, both CCOC and ENOC appear to contain subgroups with distinct metabolic mRNA expression profiles, raising the possibility that, in addition to sharing coarse clinical pathological features, ccRCC and CCOC share genomic-defined substrata. Further investigation into the metabolic landscape of these cancers is warranted, as is a recognition that subtype-specific treatments developed for ccRCC may could work for subpopulations of CCOC patients.
Ovarian and renal clear cell carcinomas 559 in ccRCC studies. The importance of cellular context in tumour behaviour was reviewed recently, and this demonstrated the intricate interplay between genomic alterations and different cellular origins of cancer [155] . We are hopeful that, if the wealth of information provided by ccRCC research guides future efforts to decipher CCOC's mutational landscape in the context of its metabolism and cells of origin, progress in managing this rarer cancer can be expedited.
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Addendum
Since the acceptance of this article, three relevant studies have been published. Espana-Agusti et al showed that pVHL loss induced replication stress in embryonic fibroblasts generated from a Vhl-/-murine model [176] . However, in mice with concurrent Pbrm and Vhl loss, this replication stress is rescued through the modification of H3K9me3-marked chromatin structure, promoting the development of ccRCC [176] . The requirement of a second mutation to maintain cellular fitness in the presence of damaging oncogenic alterations could be explored in CCOC and the context of concurrent ARID1A and PIK3CA mutations. Miao et al described the correlation of PBRM1 mutation in ccRCC patients with an immune-related RNA expression landscape and better response to immune checkpoint inhibitors compared to those without PBRM1 mutations [177] . The role of the chromatin remodeling complexes in the tumor immune response is being increasingly highlighted, where deficiency in members of the PBAF complex was shown to sensitize cancers to T-cell mediated cytotoxicity [178] . The investigation of immunotherapy in CCOC in relation to chromatin remodeling complex alterations is therefore warranted.
